Skip to main content

Table 2 Percentage of difference of PET parameters in responder group

From: A phase II clinical trial to investigate the effect of pioglitazone on 18F-FDG uptake in malignant lesions

Type of lesions

SUVmax

SUVmean

Isocontour (Bq/mL)

Isocontour-mediastinal

activity(Bq/mL)

Malignant lesion

13.82*

9.49*

19.62*,**

20.37*

Gastrointestinal cancer

25.94*

9.69

33.19*

41.59*

Hepatobiliary and pancreatic cancer

5.89

10.71*

14.40*

8.73

Hepatocellular carcinoma

7.48

3.98

2.83

5.49

Inflammatory lesion

5.95

−1.27

8.91

−14.99

  1. *P < 0.05 when compared parameters between the first day and second day
  2. **P < 0.05 when compared with difference (%) of inflammatory lesion